- Home
- AMRN vs DRUG Comparison
AMRN vs DRUG Comparison
Compare AMRN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- DRUG
- Stock Information
- Founded
- AMRN 1989
- DRUG 2019
- Country
- AMRN Ireland
- DRUG United States
- Employees
- AMRN N/A
- DRUG N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- DRUG Pharmaceuticals and Biotechnology
- Sector
- AMRN Health Care
- DRUG Health Care
- Exchange
- AMRN Nasdaq
- DRUG Nasdaq
- Market Cap
- AMRN 216.0M
- DRUG 233.2M
- IPO Year
- AMRN 1993
- DRUG N/A
- Fundamental
- Price
- AMRN $11.95
- DRUG $27.46
- Analyst Decision
- AMRN Sell
- DRUG Strong Buy
- Analyst Count
- AMRN 2
- DRUG 6
- Target Price
- AMRN $7.00
- DRUG $83.25
- AVG Volume (30 Days)
- AMRN 75.5K
- DRUG 31.5K
- Earning Date
- AMRN 05-07-2025
- DRUG 05-15-2025
- Dividend Yield
- AMRN N/A
- DRUG N/A
- EPS Growth
- AMRN N/A
- DRUG N/A
- EPS
- AMRN N/A
- DRUG N/A
- Revenue
- AMRN $214,112,000.00
- DRUG N/A
- Revenue This Year
- AMRN N/A
- DRUG N/A
- Revenue Next Year
- AMRN $5.97
- DRUG N/A
- P/E Ratio
- AMRN N/A
- DRUG N/A
- Revenue Growth
- AMRN N/A
- DRUG N/A
- 52 Week Low
- AMRN $7.08
- DRUG $0.93
- 52 Week High
- AMRN $17.58
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- AMRN 69.15
- DRUG 39.38
- Support Level
- AMRN $11.27
- DRUG $25.30
- Resistance Level
- AMRN $11.84
- DRUG $31.20
- Average True Range (ATR)
- AMRN 0.50
- DRUG 2.21
- MACD
- AMRN 0.08
- DRUG -0.35
- Stochastic Oscillator
- AMRN 83.83
- DRUG 22.59
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.